Please login to the form below

Not currently logged in
Email:
Password:

Gilead's John Martin steps down as chief executive officer

He becomes executive chairman and is replaced as CEO by John Milligan 

Gilead John MartinGilead Sciences' John Martin has stepped down as chief executive officer, a role he had held since 1996, and moved to a new role as executive chairman.

His replacement as CEO is John Milligan who joined Gilead in 1990 as a research scientist and has since held several senior management positions at the company including chief financial officer.

Martin (pictured above) started at Gilead in 1990 as vice president for research and development and has 40 years of pharmaceutical and management expertise, during which he spent time in several leadership positions at Bristol-Myers Squibb and Syntex.

He was made chairman of Gilead's board in 2008 and will now transition from CEO and chair to executive chairman over the next six weeks.

John Cogan, Gilead's lead independent director, said: “John Martin has led Gilead as chief executive officer for the past 20 years, and under his stewardship, the company has developed and delivered therapeutic advancements to millions of people around the world.

“His legacy is clear - and the vision he has set will continue with his contributions as executive chairman.”

Gilead John MilliganTaking the reins from Martin at the California-based biopharmaceutical company is John Milligan (pictured left), who currently serves as its president and chief operating officer.

Milligan will become Gilead's chief executive officer on 10 March, when he will also join the firm's board of directors.

John Martin said: “Over the past 25 years, John Milligan has distinguished himself as an exceptional leader, serving in diverse management roles and overseeing multiple phases of growth and expansion into new therapeutic areas and geographies.

“The board of directors and I are confident in his ability to lead Gilead into the future.”

3rd February 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics